1 day ago
Morgan Stanley is forecasting that Cisco (CSCO) could be entering a new period of lasting growth. According to **** yst Meta Marshall, the company appears to be entering a "more durable growth phase," as quoted by Seeking Alpha. The firm also has an "Overweight" rating on the tech giant with a price target of $135. Fueling that call are several key catalysts, including upgrades with networking equipment, demand for artificial intelligence, and cybersecurity.
One of the biggest catalysts for Morgan Stanley's bullishness is that Cisco's customers are still in the early stages of upgrading their networking equipment. As of now, Marshall says that only about 7% of Cisco's Catalyst 4K and 6K (switches that are used by companies to connect computers, phones, servers, and other devices together) have been updated so far. That means there are still plenty of other companies that will need to upgrade.
Walmart Stock Is More Expensive Than Nvidia Amid Earnings Miss
SpaceX Stock Just Crashed Below Its IPO Price: Here's the Bull Case **** ody Can Ignore
A Major Bitcoin Short Squeeze Is Taking MicroStrategy Stock Higher. What Comes Next.
#morgan #Growth #catalysts
One of the biggest catalysts for Morgan Stanley's bullishness is that Cisco's customers are still in the early stages of upgrading their networking equipment. As of now, Marshall says that only about 7% of Cisco's Catalyst 4K and 6K (switches that are used by companies to connect computers, phones, servers, and other devices together) have been updated so far. That means there are still plenty of other companies that will need to upgrade.
Walmart Stock Is More Expensive Than Nvidia Amid Earnings Miss
SpaceX Stock Just Crashed Below Its IPO Price: Here's the Bull Case **** ody Can Ignore
A Major Bitcoin Short Squeeze Is Taking MicroStrategy Stock Higher. What Comes Next.
#morgan #Growth #catalysts
2 days ago
Treasury Secretary Scott Bessent moved fast to calm the bond market this month. Two of the biggest names on Wall Street just moved just as fast to say it probably will not be enough. A rebuttal that landed within days of his own announcement.
The pushback lands at an awkward moment for Bessent. The national debt just hit a fresh milestone and a closely watched Federal Reserve speech is only days away. Both developments raise the stakes for whatever the Treasury decides to do next.
Interest rate strategists at Goldman Sachs and Wells Fargo both said the Treasury Department's expanded bond buybacks will do little to reverse the recent jump in long-term yields. Rates on 10- and 30-year Treasuries briefly dropped after the announcement, then rose again, erasing much of the initial relief, Bloomberg reported.
Goldman Sachs strategists George Cole and William Marshall wrote in an August 21 research note that the buyback expansion "does not address what we see as the main sources of recent long-end volatility." They added that the buybacks are "unlikely to meaningfully reset rate levels even if scaled up."
Wells Fargo strategists led by Erik Nelson made a similar case in their own August 21 note, arguing that lowering long-end yields would require macroeconomic shifts rather than Treasury market operations. They pointed to a slowdown in growth and inflation, less uncertainty around Federal Reserve policy, fiscal consolidation, or a decline in investment-grade corporate bond issuance as the kinds of catalysts actually needed to move yields lower.
#strategists
The pushback lands at an awkward moment for Bessent. The national debt just hit a fresh milestone and a closely watched Federal Reserve speech is only days away. Both developments raise the stakes for whatever the Treasury decides to do next.
Interest rate strategists at Goldman Sachs and Wells Fargo both said the Treasury Department's expanded bond buybacks will do little to reverse the recent jump in long-term yields. Rates on 10- and 30-year Treasuries briefly dropped after the announcement, then rose again, erasing much of the initial relief, Bloomberg reported.
Goldman Sachs strategists George Cole and William Marshall wrote in an August 21 research note that the buyback expansion "does not address what we see as the main sources of recent long-end volatility." They added that the buybacks are "unlikely to meaningfully reset rate levels even if scaled up."
Wells Fargo strategists led by Erik Nelson made a similar case in their own August 21 note, arguing that lowering long-end yields would require macroeconomic shifts rather than Treasury market operations. They pointed to a slowdown in growth and inflation, less uncertainty around Federal Reserve policy, fiscal consolidation, or a decline in investment-grade corporate bond issuance as the kinds of catalysts actually needed to move yields lower.
#strategists
8 days ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Silver (SI=F) September futures opened at $63.43 per ounce on Wednesday, August 19, 2026, down 1% from Tuesday's closing price. The silver price moved higher this morning, reaching $65 as of 8:55 a.m. ET.
Despite signs of strength Wednesday morning, the silver price is down about 9% for the year — after spiking in late January and then dipping into negative territory in March. Catalysts have included ongoing tensions in the Middle East and higher rate hike expectations. While the war in Iran is ongoing, the interest-rate outlook has improved. Silver has not meaningfully appreciated, however.
The metal's industrial applications add complexity to its price drivers relative to gold. As a result, silver tends to be far more volatile. The current gold-to-silver ratio near 68 is in line with the long-term average range of 50 and 80.
The opening price of silver futures on Wednesday, August 19, 2026, was 1% lower compared to Tuesday's closing price. Here's how today's opening silver price has changed versus last week, month, and year:
#silver #closing
Silver (SI=F) September futures opened at $63.43 per ounce on Wednesday, August 19, 2026, down 1% from Tuesday's closing price. The silver price moved higher this morning, reaching $65 as of 8:55 a.m. ET.
Despite signs of strength Wednesday morning, the silver price is down about 9% for the year — after spiking in late January and then dipping into negative territory in March. Catalysts have included ongoing tensions in the Middle East and higher rate hike expectations. While the war in Iran is ongoing, the interest-rate outlook has improved. Silver has not meaningfully appreciated, however.
The metal's industrial applications add complexity to its price drivers relative to gold. As a result, silver tends to be far more volatile. The current gold-to-silver ratio near 68 is in line with the long-term average range of 50 and 80.
The opening price of silver futures on Wednesday, August 19, 2026, was 1% lower compared to Tuesday's closing price. Here's how today's opening silver price has changed versus last week, month, and year:
#silver #closing
9 days ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Silver (SI=F) September futures opened at $63.43 per ounce on Wednesday, August 19, 2026, down 1% from Tuesday's closing price. The silver price moved higher this morning, reaching $65 as of 8:55 a.m. ET.
Despite signs of strength Wednesday morning, the silver price is down about 9% for the year — after spiking in late January and then dipping into negative territory in March. Catalysts have included ongoing tensions in the Middle East and higher rate hike expectations. While the war in Iran is ongoing, the interest-rate outlook has improved. Silver has not meaningfully appreciated, however.
The metal's industrial applications add complexity to its price drivers relative to gold. As a result, silver tends to be far more volatile. The current gold-to-silver ratio near 68 is in line with the long-term average range of 50 and 80.
The opening price of silver futures on Wednesday, August 19, 2026, was 1% lower compared to Tuesday's closing price. Here's how today's opening silver price has changed versus last week, month, and year:
#morning
Silver (SI=F) September futures opened at $63.43 per ounce on Wednesday, August 19, 2026, down 1% from Tuesday's closing price. The silver price moved higher this morning, reaching $65 as of 8:55 a.m. ET.
Despite signs of strength Wednesday morning, the silver price is down about 9% for the year — after spiking in late January and then dipping into negative territory in March. Catalysts have included ongoing tensions in the Middle East and higher rate hike expectations. While the war in Iran is ongoing, the interest-rate outlook has improved. Silver has not meaningfully appreciated, however.
The metal's industrial applications add complexity to its price drivers relative to gold. As a result, silver tends to be far more volatile. The current gold-to-silver ratio near 68 is in line with the long-term average range of 50 and 80.
The opening price of silver futures on Wednesday, August 19, 2026, was 1% lower compared to Tuesday's closing price. Here's how today's opening silver price has changed versus last week, month, and year:
#morning
9 days ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Silver (SI=F) September futures opened at $63.43 per ounce on Wednesday, August 19, 2026, down 1% from Tuesday's closing price. The silver price moved higher this morning, reaching $65 as of 8:55 a.m. ET.
Despite signs of strength Wednesday morning, the silver price is down about 9% for the year — after spiking in late January and then dipping into negative territory in March. Catalysts have included ongoing tensions in the Middle East and higher rate hike expectations. While the war in Iran is ongoing, the interest-rate outlook has improved. Silver has not meaningfully appreciated, however.
The metal's industrial applications add complexity to its price drivers relative to gold. As a result, silver tends to be far more volatile. The current gold-to-silver ratio near 68 is in line with the long-term average range of 50 and 80.
The opening price of silver futures on Wednesday, August 19, 2026, was 1% lower compared to Tuesday's closing price. Here's how today's opening silver price has changed versus last week, month, and year:
#silver #price #august
Silver (SI=F) September futures opened at $63.43 per ounce on Wednesday, August 19, 2026, down 1% from Tuesday's closing price. The silver price moved higher this morning, reaching $65 as of 8:55 a.m. ET.
Despite signs of strength Wednesday morning, the silver price is down about 9% for the year — after spiking in late January and then dipping into negative territory in March. Catalysts have included ongoing tensions in the Middle East and higher rate hike expectations. While the war in Iran is ongoing, the interest-rate outlook has improved. Silver has not meaningfully appreciated, however.
The metal's industrial applications add complexity to its price drivers relative to gold. As a result, silver tends to be far more volatile. The current gold-to-silver ratio near 68 is in line with the long-term average range of 50 and 80.
The opening price of silver futures on Wednesday, August 19, 2026, was 1% lower compared to Tuesday's closing price. Here's how today's opening silver price has changed versus last week, month, and year:
#silver #price #august
9 days ago
Ondas Holdings and Unusual Machines dropped between 7 and 8 percent as four drone stocks fell in sync, pointing to a theme unwind rather than stock-specific catalysts.
Kratos Defense fell 5% despite sitting down 20% YTD, with 30-year Treasury yields near 19-year highs amplifying pressure on high-multiple drone stocks.
Act now: the ******* yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Red Cat Holdings didn't make the cut. Grab the names FREE today.
The defense drone complex is selling off together on Thursday morning, and the shape of the move matters more than the headline attached to it. Ondas Holdings (NASDAQ:ONDS) stock is down 7% to $8.31, while Unusual Machines (NYSE:UMAC) stock is down 8% to $26.13.
Meanwhile, Red Cat Holdings (NASDAQ:RCAT) stock is down 5% to $9.36, and Kratos Defense & Security Solutions (NASDAQ:KTOS) stock is down 5% to $57.61. Four names that entered the day with wildly different year-to-date setups are all falling by similar amounts, which points to positioning as the driver.
#drone
Kratos Defense fell 5% despite sitting down 20% YTD, with 30-year Treasury yields near 19-year highs amplifying pressure on high-multiple drone stocks.
Act now: the ******* yst who called NVIDIA in 2010 just named his top 10 AI stocks — and Red Cat Holdings didn't make the cut. Grab the names FREE today.
The defense drone complex is selling off together on Thursday morning, and the shape of the move matters more than the headline attached to it. Ondas Holdings (NASDAQ:ONDS) stock is down 7% to $8.31, while Unusual Machines (NYSE:UMAC) stock is down 8% to $26.13.
Meanwhile, Red Cat Holdings (NASDAQ:RCAT) stock is down 5% to $9.36, and Kratos Defense & Security Solutions (NASDAQ:KTOS) stock is down 5% to $57.61. Four names that entered the day with wildly different year-to-date setups are all falling by similar amounts, which points to positioning as the driver.
#drone
10 days ago
Apple Inc. (NASDAQ:AAPL) received a major vote of confidence from Rothschild Redburn today, with the firm upgrading the stock from Neutral to "Buy" and raising its price target to $400 from $260. The upgrade rests on two major catalysts for Apple: its entry into premium foldables and a strategic reset to the Apple Intelligence platform.
Apple's bull case lies within its tight integration of premium hardware, proprietary silicon, and its rapidly expanding services layer. For the near future, **** yst James Cordwell anticipates iPhone sales to grow at a 12% five-year annual compound rate, roughly 3-14% above consensus expectations between fiscal 2026 and 2030.
This anticipated increase is backed by Apple's potential entry into the premium foldables market, particularly with the launch of iPhone Ultra. Not only will Apple gain a new product category with the launch, but will also be able to lift its average selling prices for the broader iPhone lineup.
This thesis is backed by numbers. The **** yst firm noted how Apple already boasts a base of 2.55 billion devices, supported by a degree of customer retention only few competitors can rival.
The second part of Apple's bull thesis, according to the firm, is its Services business. The firm believes that it is the most valuable part of Apple's franchise, growing at roughly three times the rate of Products. The business generates gross margins of roughly 75%, more than double of that earned on Product sales.
#firm #product #entry
Apple's bull case lies within its tight integration of premium hardware, proprietary silicon, and its rapidly expanding services layer. For the near future, **** yst James Cordwell anticipates iPhone sales to grow at a 12% five-year annual compound rate, roughly 3-14% above consensus expectations between fiscal 2026 and 2030.
This anticipated increase is backed by Apple's potential entry into the premium foldables market, particularly with the launch of iPhone Ultra. Not only will Apple gain a new product category with the launch, but will also be able to lift its average selling prices for the broader iPhone lineup.
This thesis is backed by numbers. The **** yst firm noted how Apple already boasts a base of 2.55 billion devices, supported by a degree of customer retention only few competitors can rival.
The second part of Apple's bull thesis, according to the firm, is its Services business. The firm believes that it is the most valuable part of Apple's franchise, growing at roughly three times the rate of Products. The business generates gross margins of roughly 75%, more than double of that earned on Product sales.
#firm #product #entry
11 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company, focusing on developing therapies for rare cardiopulmonary diseases. On August 14, 2026, Liquidia Corporation (NASDAQ:LQDA) closed at $74.44 per share. One-month return of Liquidia Corporation (NASDAQ:LQDA) was 0.26% and its shares gained 178.79% over the past 52 weeks. Liquidia Corporation (NASDAQ:LQDA) has a market capitalization of $6.66 billion.
Greenhaven Road Capital stated the following regarding Liquidia Corporation (NASDAQ:LQDA) in its Q2 2026 investor letter:
"Liquidia Corporation (NASDAQ:LQDA) — This is another special situation. The company has launched a successful drug but remains in a patent dispute that will determine how large their market can be. We purchased shares below where I believed they would settle even after an adverse trial outcome. The shares appreciated more than 30% before a verdict, so we realized a short-term gain and will revisit the investment after the decision."
Liquidia Corporation (NASDAQ:LQDA) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held Liquidia Corporation (NASDAQ:LQDA) at the end of the first quarter which was 44 in the previous quarter. While we acknowledge the potential of Liquidia Corporation (NASDAQ:LQDA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#corporation
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company, focusing on developing therapies for rare cardiopulmonary diseases. On August 14, 2026, Liquidia Corporation (NASDAQ:LQDA) closed at $74.44 per share. One-month return of Liquidia Corporation (NASDAQ:LQDA) was 0.26% and its shares gained 178.79% over the past 52 weeks. Liquidia Corporation (NASDAQ:LQDA) has a market capitalization of $6.66 billion.
Greenhaven Road Capital stated the following regarding Liquidia Corporation (NASDAQ:LQDA) in its Q2 2026 investor letter:
"Liquidia Corporation (NASDAQ:LQDA) — This is another special situation. The company has launched a successful drug but remains in a patent dispute that will determine how large their market can be. We purchased shares below where I believed they would settle even after an adverse trial outcome. The shares appreciated more than 30% before a verdict, so we realized a short-term gain and will revisit the investment after the decision."
Liquidia Corporation (NASDAQ:LQDA) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held Liquidia Corporation (NASDAQ:LQDA) at the end of the first quarter which was 44 in the previous quarter. While we acknowledge the potential of Liquidia Corporation (NASDAQ:LQDA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#corporation
11 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted AppLovin Corporation (NASDAQ:APP). AppLovin Corporation (NASDAQ:APP) is a mobile technology company specializing in developing software-based platforms for advertisers to enhance the marketing and monetization of their content. On August 14, 2026, AppLovin Corporation (NASDAQ:APP) closed at $315.44 per share, reflecting a market capitalization of $105.97 billion. AppLovin Corporation (NASDAQ:APP) posted a one-month return of -25.71%, while its shares lost 28.07% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding AppLovin Corporation (NASDAQ:APP) in its Q2 2026 investor letter:
"AppLovin Corporation (NASDAQ:APP) — This is a 1% position in a small AI basket. AppLovin is an AI company whose product happens to be ad matching. AXON predicts which ad to show to which user to maximize conversion AppLovin has been one of the best companies at using AI at scale to drive revenues and profits. In 2025 revenue grew ~70% year-over-year to $5.48B with ~82% adjusted EBITDA margin and $3.95B of free cash flow (FCF), an 88% conversion of EBITDA to FCF. In 2025 the company was a rule of 142 company with 70% revenue growth and 72% FCF margin. AppLovin should generate more than $6 million of EBITDA per employee in 2026, paring down headcount while growing at very high rates. Shares trade at sub 20X 2027 FCF."
AppLovin Corporation (NASDAQ:APP) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 91 hedge fund portfolios held AppLovin Corporation (NASDAQ:APP) at the end of the first quarter, compared to 108 in the previous quarter. While we acknowledge the potential of AppLovin Corporation (NASDAQ:APP) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#applovin #company #ebitda
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted AppLovin Corporation (NASDAQ:APP). AppLovin Corporation (NASDAQ:APP) is a mobile technology company specializing in developing software-based platforms for advertisers to enhance the marketing and monetization of their content. On August 14, 2026, AppLovin Corporation (NASDAQ:APP) closed at $315.44 per share, reflecting a market capitalization of $105.97 billion. AppLovin Corporation (NASDAQ:APP) posted a one-month return of -25.71%, while its shares lost 28.07% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding AppLovin Corporation (NASDAQ:APP) in its Q2 2026 investor letter:
"AppLovin Corporation (NASDAQ:APP) — This is a 1% position in a small AI basket. AppLovin is an AI company whose product happens to be ad matching. AXON predicts which ad to show to which user to maximize conversion AppLovin has been one of the best companies at using AI at scale to drive revenues and profits. In 2025 revenue grew ~70% year-over-year to $5.48B with ~82% adjusted EBITDA margin and $3.95B of free cash flow (FCF), an 88% conversion of EBITDA to FCF. In 2025 the company was a rule of 142 company with 70% revenue growth and 72% FCF margin. AppLovin should generate more than $6 million of EBITDA per employee in 2026, paring down headcount while growing at very high rates. Shares trade at sub 20X 2027 FCF."
AppLovin Corporation (NASDAQ:APP) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 91 hedge fund portfolios held AppLovin Corporation (NASDAQ:APP) at the end of the first quarter, compared to 108 in the previous quarter. While we acknowledge the potential of AppLovin Corporation (NASDAQ:APP) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#applovin #company #ebitda
11 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization that engages in the aseptic fill and finish of formulations and highly viscous sterile injectable pharmaceutical drug and medical device products. On August 14, 2026, Lifecore Biomedical, Inc. (NASDAQ:LFCR) closed at $4.72 per share, reflecting a market capitalization of $178.67 million. Lifecore Biomedical, Inc. (NASDAQ:LFCR) posted a one-month return of -3.41%, while its shares lost 38.78% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its Q2 2026 investor letter:
"Another top-five holding is Lifecore Biomedical, Inc. (NASDAQ:LFCR). The entire thesis is that they can sell their excess manufacturing capacity. The company has announced seven new customers in the past nine months, and while the customers are not named specifically, breadcrumbs indicate at least two large customers. For a relatively new CEO and his revamped sales team, this is tangible progress.
Public investors do not appear to fully value Lifecore's contract wins because lengthy FDA approval processes delay the ******* ociated revenue. Yet those approvals also make the contracts exceptionally sticky, a characteristic private investors are typically more willing to value. I continue to believe the shares will trade higher or the company will be sold. A recent SEC filing indicated that the company continues to evaluate a range of strategic alternatives. Insiders own more than 30% of the company, and in most scenarios I model, a sale would occur at a substantial premium to today's share price, potentially more than 100%. In my opinion, there is little to no takeover premium embedded in the price of the stock. Because Alcon's contractual minimums begin in 2027, growth should return in 2027 and accelerate in 2028. Time will tell if the company remains public."
#lifecore #quarter
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization that engages in the aseptic fill and finish of formulations and highly viscous sterile injectable pharmaceutical drug and medical device products. On August 14, 2026, Lifecore Biomedical, Inc. (NASDAQ:LFCR) closed at $4.72 per share, reflecting a market capitalization of $178.67 million. Lifecore Biomedical, Inc. (NASDAQ:LFCR) posted a one-month return of -3.41%, while its shares lost 38.78% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its Q2 2026 investor letter:
"Another top-five holding is Lifecore Biomedical, Inc. (NASDAQ:LFCR). The entire thesis is that they can sell their excess manufacturing capacity. The company has announced seven new customers in the past nine months, and while the customers are not named specifically, breadcrumbs indicate at least two large customers. For a relatively new CEO and his revamped sales team, this is tangible progress.
Public investors do not appear to fully value Lifecore's contract wins because lengthy FDA approval processes delay the ******* ociated revenue. Yet those approvals also make the contracts exceptionally sticky, a characteristic private investors are typically more willing to value. I continue to believe the shares will trade higher or the company will be sold. A recent SEC filing indicated that the company continues to evaluate a range of strategic alternatives. Insiders own more than 30% of the company, and in most scenarios I model, a sale would occur at a substantial premium to today's share price, potentially more than 100%. In my opinion, there is little to no takeover premium embedded in the price of the stock. Because Alcon's contractual minimums begin in 2027, growth should return in 2027 and accelerate in 2028. Time will tell if the company remains public."
#lifecore #quarter
11 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted KKR & Co. Inc. (NYSE:KKR). KKR & Co. Inc. (NYSE:KKR) is a leading private equity and real estate investment firm focusing on direct and fund-of-fund investments. On August 14, 2026, KKR & Co. Inc. (NYSE:KKR) closed at $114.01 per share, reflecting a market capitalization of $102.34 billion. KKR & Co. Inc. (NYSE:KKR) posted a one-month return of 13.58%, while its shares lost 22.00% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding KKR & Co. Inc. (NYSE:KKR) in its Q2 2026 investor letter:
"We still own PAR and KKR & Co. Inc. (NYSE:KKR), but they are not currently top-five holdings, so we will devote more **** e to the new investments. KKR remains a great business. I believe the private credit scare will pass and AUM will march higher, driven by the maturation of existing strategies and the development of the high-net-worth channel."
KKR & Co. Inc. (NYSE:KKR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 82 hedge fund portfolios held KKR & Co. Inc. (NYSE:KKR) at the end of the first quarter, up from 76 in the previous quarter. While we acknowledge the potential of KKR & Co. Inc. (NYSE:KKR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#investor
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted KKR & Co. Inc. (NYSE:KKR). KKR & Co. Inc. (NYSE:KKR) is a leading private equity and real estate investment firm focusing on direct and fund-of-fund investments. On August 14, 2026, KKR & Co. Inc. (NYSE:KKR) closed at $114.01 per share, reflecting a market capitalization of $102.34 billion. KKR & Co. Inc. (NYSE:KKR) posted a one-month return of 13.58%, while its shares lost 22.00% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding KKR & Co. Inc. (NYSE:KKR) in its Q2 2026 investor letter:
"We still own PAR and KKR & Co. Inc. (NYSE:KKR), but they are not currently top-five holdings, so we will devote more **** e to the new investments. KKR remains a great business. I believe the private credit scare will pass and AUM will march higher, driven by the maturation of existing strategies and the development of the high-net-worth channel."
KKR & Co. Inc. (NYSE:KKR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 82 hedge fund portfolios held KKR & Co. Inc. (NYSE:KKR) at the end of the first quarter, up from 76 in the previous quarter. While we acknowledge the potential of KKR & Co. Inc. (NYSE:KKR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#investor
11 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted PAR Technology Corporation (NYSE:PAR). PAR Technology Corporation (NYSE:PAR) is a leading technology company that offers cloud-based hardware and software solutions to the restaurant and retail industries. On August 14, 2026, PAR Technology Corporation (NYSE:PAR) closed at $19.05 per share. One-month return of PAR Technology Corporation (NYSE:PAR) was 13.25%, and its shares lost 64.50% over the past 52 weeks. PAR Technology Corporation (NYSE:PAR) has a market capitalization of $787.96 million.
Greenhaven Road Capital stated the following regarding PAR Technology Corporation (NYSE:PAR) in its Q2 2026 investor letter:
"We still own PAR Technology Corporation (NYSE:PAR) and KKR, but they are not currently top-five holdings, so we will devote more ******* e to the new investments. My view on PAR remains that there is a long runway for growth and that the company has inflected to EBITDA profitability. If our view is variant, it is in two places: ******* ysts are significantly underestimating 2027 EBITDA and underestimating PAR's chances of winning McDonald's."
PAR Technology Corporation (NYSE:PAR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 31 hedge fund portfolios held PAR Technology Corporation (NYSE:PAR) at the end of the first quarter, up from 27 in the previous quarter. While we acknowledge the potential of PAR Technology Corporation (NYSE:PAR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#technology #corporation #letter #company
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted PAR Technology Corporation (NYSE:PAR). PAR Technology Corporation (NYSE:PAR) is a leading technology company that offers cloud-based hardware and software solutions to the restaurant and retail industries. On August 14, 2026, PAR Technology Corporation (NYSE:PAR) closed at $19.05 per share. One-month return of PAR Technology Corporation (NYSE:PAR) was 13.25%, and its shares lost 64.50% over the past 52 weeks. PAR Technology Corporation (NYSE:PAR) has a market capitalization of $787.96 million.
Greenhaven Road Capital stated the following regarding PAR Technology Corporation (NYSE:PAR) in its Q2 2026 investor letter:
"We still own PAR Technology Corporation (NYSE:PAR) and KKR, but they are not currently top-five holdings, so we will devote more ******* e to the new investments. My view on PAR remains that there is a long runway for growth and that the company has inflected to EBITDA profitability. If our view is variant, it is in two places: ******* ysts are significantly underestimating 2027 EBITDA and underestimating PAR's chances of winning McDonald's."
PAR Technology Corporation (NYSE:PAR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 31 hedge fund portfolios held PAR Technology Corporation (NYSE:PAR) at the end of the first quarter, up from 27 in the previous quarter. While we acknowledge the potential of PAR Technology Corporation (NYSE:PAR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#technology #corporation #letter #company
11 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted AnaptysBio, Inc. (NASDAQ:ANAB) as a newly added position. AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company focusing on immunology therapeutics for autoimmune and inflammatory diseases. On August 14, 2026, AnaptysBio, Inc. (NASDAQ:ANAB) closed at $58.47 per share, reflecting a market capitalization of $1.73 billion. AnaptysBio, Inc. (NASDAQ:ANAB) posted a one-month return of 16.27%, while its shares gained 338.15% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding AnaptysBio, Inc. (NASDAQ:ANAB) in its Q2 2026 investor letter:
"Many of our investments require patience. Rather than a clear near-term catalyst, they offer an advantaged product or management team that can build the business and compound value over time. This quarter, we invested in AnaptysBio, a situation that may not require as much patience.
AnaptysBio, Inc. (NASDAQ:ANAB) is a drug royalty company. In 2014, Tesaro licensed a portfolio of pre-clinical antibodies from AnaptysBio. Tesaro, then a small company with $180M in cash, paid AnaptysBio $17M under an agreement designed for two small companies. The agreement included exclusivity and notification provisions and required Tesaro to seek an "optimal commercial return" for AnaptysBio's drugs, which were still in clinical trials.
#road #company #letter
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted AnaptysBio, Inc. (NASDAQ:ANAB) as a newly added position. AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company focusing on immunology therapeutics for autoimmune and inflammatory diseases. On August 14, 2026, AnaptysBio, Inc. (NASDAQ:ANAB) closed at $58.47 per share, reflecting a market capitalization of $1.73 billion. AnaptysBio, Inc. (NASDAQ:ANAB) posted a one-month return of 16.27%, while its shares gained 338.15% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding AnaptysBio, Inc. (NASDAQ:ANAB) in its Q2 2026 investor letter:
"Many of our investments require patience. Rather than a clear near-term catalyst, they offer an advantaged product or management team that can build the business and compound value over time. This quarter, we invested in AnaptysBio, a situation that may not require as much patience.
AnaptysBio, Inc. (NASDAQ:ANAB) is a drug royalty company. In 2014, Tesaro licensed a portfolio of pre-clinical antibodies from AnaptysBio. Tesaro, then a small company with $180M in cash, paid AnaptysBio $17M under an agreement designed for two small companies. The agreement included exclusivity and notification provisions and required Tesaro to seek an "optimal commercial return" for AnaptysBio's drugs, which were still in clinical trials.
#road #company #letter
11 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Burford Capital Limited (NYSE:BUR). Burford Capital Limited (NYSE:BUR) is a leading legal finance company that offers litigation finance, ****** et recovery and ****** et management services. On August 14, 2026, Burford Capital Limited (NYSE:BUR) closed at $4.37 per share, reflecting a market capitalization of $959.58 million. Burford Capital Limited (NYSE:BUR) posted a one‑month return of 8.71%, while its shares lost 67.89% over the past 52 weeks."
Greenhaven Road Capital stated the following regarding Burford Capital Limited (NYSE:BUR) in its Q2 2026 investor letter:
"Burford Capital Limited (NYSE:BUR) is the 800-pound gorilla of litigation finance. It sees the most cases and has the best settlement data, giving it an advantage in selecting and funding cases profitably. More than 285 funded cases have concluded; 90% ended in a win or profitable settlement. Those investments produced an 82% return on invested capital over a weighted average life of 2.6 years, resulting in a 25% IRR.
As outlined in previous letters and the presentation sent last quarter, Burford has invested more than $150M in price-fixing cases involving proteins—chicken, beef, turkey, and pork. For much of that capital, Burford retains all of the upside rather than sharing it with a client, and it controls when the cases settle.
#capital #limited #road
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Burford Capital Limited (NYSE:BUR). Burford Capital Limited (NYSE:BUR) is a leading legal finance company that offers litigation finance, ****** et recovery and ****** et management services. On August 14, 2026, Burford Capital Limited (NYSE:BUR) closed at $4.37 per share, reflecting a market capitalization of $959.58 million. Burford Capital Limited (NYSE:BUR) posted a one‑month return of 8.71%, while its shares lost 67.89% over the past 52 weeks."
Greenhaven Road Capital stated the following regarding Burford Capital Limited (NYSE:BUR) in its Q2 2026 investor letter:
"Burford Capital Limited (NYSE:BUR) is the 800-pound gorilla of litigation finance. It sees the most cases and has the best settlement data, giving it an advantage in selecting and funding cases profitably. More than 285 funded cases have concluded; 90% ended in a win or profitable settlement. Those investments produced an 82% return on invested capital over a weighted average life of 2.6 years, resulting in a 25% IRR.
As outlined in previous letters and the presentation sent last quarter, Burford has invested more than $150M in price-fixing cases involving proteins—chicken, beef, turkey, and pork. For much of that capital, Burford retains all of the upside rather than sharing it with a client, and it controls when the cases settle.
#capital #limited #road
11 days ago
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, alongside a proactive stance on profit-taking. The focus will remain on owning strong businesses and conducting research that challenges consensus views, as several major investments are poised for significant events within the year. Despite declines in market multiples, underlying businesses continue to grow, suggesting a favorable positioning for returns. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Kingsway Corporation (NYSE:KWY). Kingsway Financial Services Inc. changed its name to Kingsway Corporation (NYSE:KWY) in May 2026. Kingsway Corporation (NYSE:KWY) is a Chicago-based holding company that operates in extended warranty and business services. On August 14, 2026, Kingsway Corporation (NYSE:KWY) closed at $9.94 per share, reflecting a market capitalization of $284.54 million. Kingsway Corporation (NYSE:KWY) posted a one‑month return of 4.85%, while its shares lost 29.50% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding Kingsway Corporation (NYSE:KWY) in its Q2 2026 investor letter:
"With no sell-side coverage and roughly 60% insider ownership, Kingsway Corporation (NYSE:KWY) is effectively ignored by the market. The free float is small, and the business is genuinely hard to **** yze. It is transforming from a messy conglomerate into an N of 1 public company built around the search model. A legacy warranty business still has to be sold, but the signs of progress are tangible: management has **** embled a portfolio of nine companies.
In the first two years after an acquisition, earnings are typically depressed while capital goes into professionalizing the business and building out sales. Even so, the ramp in quarterly EBITDA for the KSX (Search) segment is already visible. Eight quarters ago, segment EBITDA was $1.4M. It nearly doubled to $2.6M two quarters ago, and last quarter it reached $3.5M, in a seasonally slow period. Given guidance for organic growth and the strength of the underlying businesses, there is a credible path to segment EBITDA of $6M+ per quarter this year..." (Click here to read the full text)
#road #letter #business
In its Q2 2026 investor letter, Greenhaven Road Capital highlighted Kingsway Corporation (NYSE:KWY). Kingsway Financial Services Inc. changed its name to Kingsway Corporation (NYSE:KWY) in May 2026. Kingsway Corporation (NYSE:KWY) is a Chicago-based holding company that operates in extended warranty and business services. On August 14, 2026, Kingsway Corporation (NYSE:KWY) closed at $9.94 per share, reflecting a market capitalization of $284.54 million. Kingsway Corporation (NYSE:KWY) posted a one‑month return of 4.85%, while its shares lost 29.50% over the past 52 weeks.
Greenhaven Road Capital stated the following regarding Kingsway Corporation (NYSE:KWY) in its Q2 2026 investor letter:
"With no sell-side coverage and roughly 60% insider ownership, Kingsway Corporation (NYSE:KWY) is effectively ignored by the market. The free float is small, and the business is genuinely hard to **** yze. It is transforming from a messy conglomerate into an N of 1 public company built around the search model. A legacy warranty business still has to be sold, but the signs of progress are tangible: management has **** embled a portfolio of nine companies.
In the first two years after an acquisition, earnings are typically depressed while capital goes into professionalizing the business and building out sales. Even so, the ramp in quarterly EBITDA for the KSX (Search) segment is already visible. Eight quarters ago, segment EBITDA was $1.4M. It nearly doubled to $2.6M two quarters ago, and last quarter it reached $3.5M, in a seasonally slow period. Given guidance for organic growth and the strength of the underlying businesses, there is a credible path to segment EBITDA of $6M+ per quarter this year..." (Click here to read the full text)
#road #letter #business
14 days ago
Amar'e Stoudemire, who is being inducted into the Naismith Basketball Hall of Fame, was one of the handful of high school players to make the jump to the NBA and be successful.
He was selected with the ninth overall pick in the 2002 NBA Draft by the Phoenix Suns and made an immediate impact, winning the 2002-03 NBA Rookie of the Year.
As one of the catalysts of Mike D'Antoni's "Seven Seconds or Less" philosophy, along with fellow Hall of Famer Steve Nash, Stoudemire blossomed into one of the league's best power forwards before knee injuries slowed his career.
Stoudemire averaged 21.4 points and 8.3 rebounds during his first eight seasons with the Suns, then signed a five-year, $99.7 million contract with the New York Knicks.
Stoudemire finished his 14-year NBA career (2002-16) averaging 18.9 points and 7.8 rebounds, making six All-Star appearances.
#stoudemire #amar 'e #Basketball
He was selected with the ninth overall pick in the 2002 NBA Draft by the Phoenix Suns and made an immediate impact, winning the 2002-03 NBA Rookie of the Year.
As one of the catalysts of Mike D'Antoni's "Seven Seconds or Less" philosophy, along with fellow Hall of Famer Steve Nash, Stoudemire blossomed into one of the league's best power forwards before knee injuries slowed his career.
Stoudemire averaged 21.4 points and 8.3 rebounds during his first eight seasons with the Suns, then signed a five-year, $99.7 million contract with the New York Knicks.
Stoudemire finished his 14-year NBA career (2002-16) averaging 18.9 points and 7.8 rebounds, making six All-Star appearances.
#stoudemire #amar 'e #Basketball
14 days ago
Datadog, Inc. (NASDAQ:DDOG) is a cloud infrastructure and application monitoring platform. Its shares are up by 102% over the past year and by 88% year-to-date. The shares closed a stunning 19% lower on August 6th after Datadog, Inc. (NASDAQ:DDOG) reported its second quarter earnings. On that same day, Cramer commented on the stock as the earnings hit the wires and called it a momentum play:
"I look at a company like DataDog, and DataDog, I'm going to be a little glib here by saying, people think it never misses. Now, when you go over DataDog line by line by line, and it's not that big. . .They're just momentum stocks, that people think, you know what, aren't so good."
As is the case with most software stocks, Datadog, Inc. (NASDAQ:DDOG)'s narrative is also about whether the firm will be able to stand on its own against the rise in AI platforms that enable businesses to develop their own software. On this front, the second quarter earnings provided key insights into the split between the bulls and the bears. During the quarter, Datadog, Inc. (NASDAQ:DDOG)'s revenue grew by 36% annually. The firm also raised its full year revenue per share guidance to $4.45 - $4.47 and its earnings per share outlook to $2.50 - $2.54. The positive aspects of the earnings led Datadog, Inc. (NASDAQ:DDOG)'s bulls to point out that the firm was experiencing significant tailwinds from AI catalysts.
However, the bears counter by pointing towards Datadog, Inc. (NASDAQ:DDOG)'s full year revenue outlook. While the firm increased the full year revenue guidance to $4.45 billion to $4.47 billion, this figure fell below the ***** yst estimates of $4.69 billion. Behind the miss was Datadog, Inc. (NASDAQ:DDOG)'s announcement that a major AI company was dialing down its usage. While Datadog, Inc. (NASDAQ:DDOG) didn't disclose the customer's name, some ***** ysts were worried about OpenAI reducing usage before the earnings. The bears use this development to argue that future similar departures could create tailwinds for Datadog, Inc. (NASDAQ:DDOG). The bears combine these worries with the firm's high forward P/E ratio of 107 to remark that the firm could suffer more than most.
Shifting towards the hedge funds, 75 out of the 1,041 hedge funds part of Insider Monkey's Q4 2025 database had held Datadog, Inc. (NASDAQ:DDOG)'s shares. This figure jumped to 80 out of 1,022 funds in Q1 2026. In terms of movement, the hedge fund stakes are quite interesting. In Q1, the biggest stakeholder was Citadel Investment Group, whose $319 million stake marked a 200% jump. Others, such as Millennium Management and Balyasny ***** et Management grew their stakes by 740% and 1,663%. Short interest as a percentage of float was 4% as of July end.
#datadog #NASDAQ #bears #revenue
"I look at a company like DataDog, and DataDog, I'm going to be a little glib here by saying, people think it never misses. Now, when you go over DataDog line by line by line, and it's not that big. . .They're just momentum stocks, that people think, you know what, aren't so good."
As is the case with most software stocks, Datadog, Inc. (NASDAQ:DDOG)'s narrative is also about whether the firm will be able to stand on its own against the rise in AI platforms that enable businesses to develop their own software. On this front, the second quarter earnings provided key insights into the split between the bulls and the bears. During the quarter, Datadog, Inc. (NASDAQ:DDOG)'s revenue grew by 36% annually. The firm also raised its full year revenue per share guidance to $4.45 - $4.47 and its earnings per share outlook to $2.50 - $2.54. The positive aspects of the earnings led Datadog, Inc. (NASDAQ:DDOG)'s bulls to point out that the firm was experiencing significant tailwinds from AI catalysts.
However, the bears counter by pointing towards Datadog, Inc. (NASDAQ:DDOG)'s full year revenue outlook. While the firm increased the full year revenue guidance to $4.45 billion to $4.47 billion, this figure fell below the ***** yst estimates of $4.69 billion. Behind the miss was Datadog, Inc. (NASDAQ:DDOG)'s announcement that a major AI company was dialing down its usage. While Datadog, Inc. (NASDAQ:DDOG) didn't disclose the customer's name, some ***** ysts were worried about OpenAI reducing usage before the earnings. The bears use this development to argue that future similar departures could create tailwinds for Datadog, Inc. (NASDAQ:DDOG). The bears combine these worries with the firm's high forward P/E ratio of 107 to remark that the firm could suffer more than most.
Shifting towards the hedge funds, 75 out of the 1,041 hedge funds part of Insider Monkey's Q4 2025 database had held Datadog, Inc. (NASDAQ:DDOG)'s shares. This figure jumped to 80 out of 1,022 funds in Q1 2026. In terms of movement, the hedge fund stakes are quite interesting. In Q1, the biggest stakeholder was Citadel Investment Group, whose $319 million stake marked a 200% jump. Others, such as Millennium Management and Balyasny ***** et Management grew their stakes by 740% and 1,663%. Short interest as a percentage of float was 4% as of July end.
#datadog #NASDAQ #bears #revenue
15 days ago
On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm's total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed 7% CER to £2.80 billion and Core EPS rose 9% CER to 50.5p. Growth was primarily fueled by double-digit gains in Specialty Medicines (+14% CER to £3.8 billion) and robust momentum in Vaccines (+8% CER to £2.3 billion). However, Total operating profit dropped 75% CER to £481 million, hit by a £1.3 billion non-cash impairment charge following the decision to discontinue camlipixant after CALM-1/2 Phase III trial results.
Alongside earnings, GSK outlined major strategic plans to accelerate its R&D roadmap. Management announced it expects 20+ Phase III trial starts in 2026, up from its previous projection of 10, focusing on 7 key **** et accelerations across 18 indications in oncology, respiratory, hepatology, and vaccines.
To support this pipeline expansion and fund late-stage development, GSK initiated its new 'Accelerate Growth' restructuring program. The three-year initiative aims to generate £1.9 billion in annual cost savings by 2029 for total costs of £2.4 billion, with savings earmarked for pipeline reinvestment and supporting operating margins through the dolutegravir loss-of-exclusivity period (2028–2030). Additionally, ViiV Healthcare, GSK's majority-owned HIV business, presented positive Phase IIIb VOGUE study data, reinforcing the efficacy and real-world utility of its long-acting HIV regimen portfolio.
This brings up a key question: Is GSK plc (NYSE:GSK)'s pipeline acceleration and core business growth enough to offset upcoming patent expiries, or does statutory margin volatility signal deeper pipeline execution risks ahead?
Bullish **** ysts highlight that GSK plc's core business model continues to show high execution efficiency, supported by key product launches and pipeline catalysts over the next 12 months that build confidence in reaching its £40 billion sales target by 2031. A critical driver is GSK plc's active business development strategy, illustrated by the acquisition of efimosfermin, which expands its hepatology portfolio, provides optionality for related liver diseases, and seamlessly aligns with corporate M&A goals.
#phase #business #operating
Alongside earnings, GSK outlined major strategic plans to accelerate its R&D roadmap. Management announced it expects 20+ Phase III trial starts in 2026, up from its previous projection of 10, focusing on 7 key **** et accelerations across 18 indications in oncology, respiratory, hepatology, and vaccines.
To support this pipeline expansion and fund late-stage development, GSK initiated its new 'Accelerate Growth' restructuring program. The three-year initiative aims to generate £1.9 billion in annual cost savings by 2029 for total costs of £2.4 billion, with savings earmarked for pipeline reinvestment and supporting operating margins through the dolutegravir loss-of-exclusivity period (2028–2030). Additionally, ViiV Healthcare, GSK's majority-owned HIV business, presented positive Phase IIIb VOGUE study data, reinforcing the efficacy and real-world utility of its long-acting HIV regimen portfolio.
This brings up a key question: Is GSK plc (NYSE:GSK)'s pipeline acceleration and core business growth enough to offset upcoming patent expiries, or does statutory margin volatility signal deeper pipeline execution risks ahead?
Bullish **** ysts highlight that GSK plc's core business model continues to show high execution efficiency, supported by key product launches and pipeline catalysts over the next 12 months that build confidence in reaching its £40 billion sales target by 2031. A critical driver is GSK plc's active business development strategy, illustrated by the acquisition of efimosfermin, which expands its hepatology portfolio, provides optionality for related liver diseases, and seamlessly aligns with corporate M&A goals.
#phase #business #operating
15 days ago
AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08–$14.28.
Adding to its commercial trajectory, AbbVie's Allergan Aesthetics announced on July 17 that the European Commission approved Boey (trenibotulinumtoxinE) across all 30 European Economic Area countries. Marked as the first and only rapid-onset, short-duration botulinum neurotoxin serotype E in Europe, Boey targets the temporary improvement of moderate to severe frown lines with an onset as fast as eight hours and results lasting two to three weeks. This regulatory milestone follows approval in Canada earlier in the year and expands AbbVie's high-margin aesthetic portfolio beyond traditional Botox offerings.
Following these catalysts, Wall Street **** yst revisions have turned increasingly positive. On July 22, Canaccord raised its price target on AbbVie to $282 from $273 while maintaining a Buy rating. The firm updated its financial model ahead of Q2 earnings, citing expected strength across core prescription volume trends and recent positive developmental wins.
This momentum brings up a pivotal question: Does AbbVie's successful pivot away from legacy reliance justify higher valuation multiples, or do long-term debt levels and margin pressures cap future upside?
Proponents of the bullish case emphasize AbbVie Inc. (NYSE:ABBV)'s high-performing post-Humira growth engine. Top-line expansion is overwhelmingly driven by its flagship immunology **** ets, Skyrizi and Rinvoq, which generated $4.483 billion (+30.9% reported) and $2.119 billion (+23.3% reported) in Q1 net revenues, respectively. Rapid, durable share gains across multiple indication rollouts highlight a strong product-market fit that effectively absorbs legacy biosimilar erosion.
#diluted
Adding to its commercial trajectory, AbbVie's Allergan Aesthetics announced on July 17 that the European Commission approved Boey (trenibotulinumtoxinE) across all 30 European Economic Area countries. Marked as the first and only rapid-onset, short-duration botulinum neurotoxin serotype E in Europe, Boey targets the temporary improvement of moderate to severe frown lines with an onset as fast as eight hours and results lasting two to three weeks. This regulatory milestone follows approval in Canada earlier in the year and expands AbbVie's high-margin aesthetic portfolio beyond traditional Botox offerings.
Following these catalysts, Wall Street **** yst revisions have turned increasingly positive. On July 22, Canaccord raised its price target on AbbVie to $282 from $273 while maintaining a Buy rating. The firm updated its financial model ahead of Q2 earnings, citing expected strength across core prescription volume trends and recent positive developmental wins.
This momentum brings up a pivotal question: Does AbbVie's successful pivot away from legacy reliance justify higher valuation multiples, or do long-term debt levels and margin pressures cap future upside?
Proponents of the bullish case emphasize AbbVie Inc. (NYSE:ABBV)'s high-performing post-Humira growth engine. Top-line expansion is overwhelmingly driven by its flagship immunology **** ets, Skyrizi and Rinvoq, which generated $4.483 billion (+30.9% reported) and $2.119 billion (+23.3% reported) in Q1 net revenues, respectively. Rapid, durable share gains across multiple indication rollouts highlight a strong product-market fit that effectively absorbs legacy biosimilar erosion.
#diluted
15 days ago
Coinbase (NASDAQ: COIN) CEO Brian Armstrong recently claimed crypto "doesn't get enough credit for the financial access it's already unlocked for the world" in a post on X. Armstrong noted that stablecoins allowed "anyone, anywhere" to access a low-inflation currency and send it "24/7 for a fraction of a cent", that decentralized finance (DeFi) applications gave "anyone access to credit" and unbanked individuals access to financial services, and that tokenized stocks would expose four billion "unbrokered people" to the U.S. stock market.
Armstrong's bullish take isn't surprising, since Coinbase is one of the world's largest cryptocurrency exchanges. If you agree with Armstrong's perspective, then it might be a good time to review how those catalysts could boost your crypto portfolio's long-term returns.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
The market's largest stablecoins, Tether (CRYPTO: USDT) and USD Coin (CRYPTO: USDC), are pegged to the U.S. dollar. Tether is more widely used overseas, while USD Coin -- which is only minted by Circle (NYSE: CRCL) -- is the leading stablecoin in the U.S. market.
Stablecoins can be deposited into third-party lending markets, automated market makers, and liquidity pools to earn higher yields than traditional dollar-based savings accounts. However, some of those platforms are much riskier than FDIC-backed banking accounts.
#stablecoins
Armstrong's bullish take isn't surprising, since Coinbase is one of the world's largest cryptocurrency exchanges. If you agree with Armstrong's perspective, then it might be a good time to review how those catalysts could boost your crypto portfolio's long-term returns.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
The market's largest stablecoins, Tether (CRYPTO: USDT) and USD Coin (CRYPTO: USDC), are pegged to the U.S. dollar. Tether is more widely used overseas, while USD Coin -- which is only minted by Circle (NYSE: CRCL) -- is the leading stablecoin in the U.S. market.
Stablecoins can be deposited into third-party lending markets, automated market makers, and liquidity pools to earn higher yields than traditional dollar-based savings accounts. However, some of those platforms are much riskier than FDIC-backed banking accounts.
#stablecoins
18 days ago
U.S. Dollar Index gains some ground as traders focus on the strong rally in the oil markets. Oil prices are up by +5% as U.S. and Iran did not reach any deal over the weekend. President Trump signaled that he would use economic pressure to force Iran back to negotiations.
High oil prices may push inflation towards higher levels and force the Fed to raise rates at the next meeting in September, which will be bullish for the American currency.
The nearest resistance level for U.S. Dollar Index is located in the 99.85 – 100.00 range. In case U.S. Dollar Index manages to settle above the 100.00 level, it will head towards the next resistance, which is located in the 100.50 – 100.65 range.
EUR/USD moved lower as traders took some profits off the table near multi-week highs. There are no important economic reports scheduled to be released in the EU today, so traders will stay focused on general market sentiment.
The nearest support level for EUR/USD is located in the 1.1510 – 1.1525 range. If EUR/USD declines below the 1.1510 level, it will head towards the next support at 1.1435 – 1.1450. RSI is in the moderate territory, so there is plenty of room to gain additional downside momentum in case the right catalysts emerge.
#next
High oil prices may push inflation towards higher levels and force the Fed to raise rates at the next meeting in September, which will be bullish for the American currency.
The nearest resistance level for U.S. Dollar Index is located in the 99.85 – 100.00 range. In case U.S. Dollar Index manages to settle above the 100.00 level, it will head towards the next resistance, which is located in the 100.50 – 100.65 range.
EUR/USD moved lower as traders took some profits off the table near multi-week highs. There are no important economic reports scheduled to be released in the EU today, so traders will stay focused on general market sentiment.
The nearest support level for EUR/USD is located in the 1.1510 – 1.1525 range. If EUR/USD declines below the 1.1510 level, it will head towards the next support at 1.1435 – 1.1450. RSI is in the moderate territory, so there is plenty of room to gain additional downside momentum in case the right catalysts emerge.
#next
18 days ago
US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index's 23% return. A copy of the letter can be downloaded here. The second quarter results were a complete reversal of Q1 results, with the portfolio appreciating 23.0% (gross) and 23.3% (net), outperforming the index's 17.3%. The overall market surge contributed to this performance, alongside several positive developments related to the firm's holdings. Since inception, the fund has returned ~16% gross and ~12% net per annum, surpassing the benchmark's return of ~9% per annum. The portfolio is highly concentrated, with QDEL as the largest holding, creating volatility. Despite mixed results, the firm remains confident in the portfolio, particularly with QDEL viewed as a key investment opportunity. Potential for further growth is expected from several large investments with promising catalysts. In addition, you can check the Strategy's top 5 holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, McIntyre Partnerships highlighted Star Holdings (NASDAQ:STHO). Star Holdings (NASDAQ:STHO) is a real estate company that engages in non-ground lease-related businesses. On August 7, 2026, Star Holdings (NASDAQ:STHO) closed at $9.64 per share. The one-month return of Star Holdings (NASDAQ:STHO) was 5.47%, and its shares gained 32.97% over the past 52 weeks. Star Holdings (NASDAQ:STHO) has a market capitalization of $116.54 million.
McIntyre Partnerships stated the following regarding Star Holdings (NASDAQ:STHO) in its Q2 2026 investor letter:
"2026 has been a decent year for Star Holdings (NASDAQ:STHO), with shares rallying ~14% YTD. However, it has been a substantially better fundamental year, with SAFE rallying ~20%. For perspective, based solely on SAFE's share price appreciation, STHO would have appreciated approximately 36%. Further, STHO has made significant progress in unwinding its legacy holdings. I estimate STHO's current NAV is ~$24.50, a 160% premium, and that the company will be able to return significant capital in 2027, if not sooner.
Regarding SAFE, Q2 marked STHO's best fundamental performance since we began purchasing STHO, with origination volumes returning to a four-year high and the company implementing its first share buyback, retiring ~2% of shares outstanding. Most importantly, SAFE sold a portfolio at a ~4.1% cap rate, which compares favorably to SAFE's current implied cap rate of ~5.3%. Applying a 4.1% cap rate, SAFE would be valued at $37/sh. versus its $16 trading price. While the remaining properties could warrant a lower multiple, if SAFE were to close its valuation gap, our STHO investment would benefit substantially."
#stho #company #return
In its Q2 2026 investor letter, McIntyre Partnerships highlighted Star Holdings (NASDAQ:STHO). Star Holdings (NASDAQ:STHO) is a real estate company that engages in non-ground lease-related businesses. On August 7, 2026, Star Holdings (NASDAQ:STHO) closed at $9.64 per share. The one-month return of Star Holdings (NASDAQ:STHO) was 5.47%, and its shares gained 32.97% over the past 52 weeks. Star Holdings (NASDAQ:STHO) has a market capitalization of $116.54 million.
McIntyre Partnerships stated the following regarding Star Holdings (NASDAQ:STHO) in its Q2 2026 investor letter:
"2026 has been a decent year for Star Holdings (NASDAQ:STHO), with shares rallying ~14% YTD. However, it has been a substantially better fundamental year, with SAFE rallying ~20%. For perspective, based solely on SAFE's share price appreciation, STHO would have appreciated approximately 36%. Further, STHO has made significant progress in unwinding its legacy holdings. I estimate STHO's current NAV is ~$24.50, a 160% premium, and that the company will be able to return significant capital in 2027, if not sooner.
Regarding SAFE, Q2 marked STHO's best fundamental performance since we began purchasing STHO, with origination volumes returning to a four-year high and the company implementing its first share buyback, retiring ~2% of shares outstanding. Most importantly, SAFE sold a portfolio at a ~4.1% cap rate, which compares favorably to SAFE's current implied cap rate of ~5.3%. Applying a 4.1% cap rate, SAFE would be valued at $37/sh. versus its $16 trading price. While the remaining properties could warrant a lower multiple, if SAFE were to close its valuation gap, our STHO investment would benefit substantially."
#stho #company #return
18 days ago
US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index's 23% return. A copy of the letter can be downloaded here. The second quarter results were a complete reversal of Q1 results, with the portfolio appreciating 23.0% (gross) and 23.3% (net), outperforming the index's 17.3%. The overall market surge contributed to this performance, alongside several positive developments related to the firm's holdings. Since inception, the fund has returned ~16% gross and ~12% net per annum, surpassing the benchmark's return of ~9% per annum. The portfolio is highly concentrated, with QDEL as the largest holding, creating volatility. Despite mixed results, the firm remains confident in the portfolio, particularly with QDEL viewed as a key investment opportunity. Potential for further growth is expected from several large investments with promising catalysts. In addition, you can check the Strategy's top 5 holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, McIntyre Partnerships highlighted Sotera Health Company (NASDAQ:SHC). Sotera Health Company (NASDAQ:SHC) is a US-based company that provides sterilization solutions, lab testing, and advisory services for the healthcare industry. On August 7, 2026, Sotera Health Company (NASDAQ:SHC) closed at $18.86 per share, reflecting a market capitalization of $5.38 billion. Sotera Health Company (NASDAQ:SHC) posted a one-month return of 5.04%, while its shares gained 25.61% over the past 52 weeks.
McIntyre Partnerships stated the following regarding Sotera Health Company (NASDAQ:SHC) in its Q2 2026 investor letter:
"Sotera Health Company (NASDAQ:SHC) saw positive Q1 results, with the key Sterigenics segment continuing its return to HSD organic growth following the COVID destocking in 2023 and 2024. Further, SHC also had positive legal news regarding its Georgia litigation, where the judge threw out 5 lawsuits with reasoning that implies the remaining 450 cases are likely to be rejected as well. While I believe the judge's ruling implies current liability is sub-$50MM, I estimate a worst-case $400k per case settlement, or $180MM, even if appeals reverse the decision. This compares to SHC's 2026 EBITDA of ~$640MM. The company also saw a CEO transition, with its long-time CEO transitioning to Executive Chairman and the hiring of CEO Shader from Viant, a medical device services company where he served as CEO. We are encouraged that former CEO Petras remains on the board and intends to play an active role in ensuring a smooth transition.
Finally, and most importantly, following Q1 earnings, SHC's former private equity owners sold the last of their shares. I believe the PE firms' selling pressure, via predictable quarterly block trades, has been a considerable overhang on SHC's shares over the past year. With this overhang gone, I believe SHC is well positioned to reweight towards peers. I es
In its Q2 2026 investor letter, McIntyre Partnerships highlighted Sotera Health Company (NASDAQ:SHC). Sotera Health Company (NASDAQ:SHC) is a US-based company that provides sterilization solutions, lab testing, and advisory services for the healthcare industry. On August 7, 2026, Sotera Health Company (NASDAQ:SHC) closed at $18.86 per share, reflecting a market capitalization of $5.38 billion. Sotera Health Company (NASDAQ:SHC) posted a one-month return of 5.04%, while its shares gained 25.61% over the past 52 weeks.
McIntyre Partnerships stated the following regarding Sotera Health Company (NASDAQ:SHC) in its Q2 2026 investor letter:
"Sotera Health Company (NASDAQ:SHC) saw positive Q1 results, with the key Sterigenics segment continuing its return to HSD organic growth following the COVID destocking in 2023 and 2024. Further, SHC also had positive legal news regarding its Georgia litigation, where the judge threw out 5 lawsuits with reasoning that implies the remaining 450 cases are likely to be rejected as well. While I believe the judge's ruling implies current liability is sub-$50MM, I estimate a worst-case $400k per case settlement, or $180MM, even if appeals reverse the decision. This compares to SHC's 2026 EBITDA of ~$640MM. The company also saw a CEO transition, with its long-time CEO transitioning to Executive Chairman and the hiring of CEO Shader from Viant, a medical device services company where he served as CEO. We are encouraged that former CEO Petras remains on the board and intends to play an active role in ensuring a smooth transition.
Finally, and most importantly, following Q1 earnings, SHC's former private equity owners sold the last of their shares. I believe the PE firms' selling pressure, via predictable quarterly block trades, has been a considerable overhang on SHC's shares over the past year. With this overhang gone, I believe SHC is well positioned to reweight towards peers. I es
18 days ago
US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index's 23% return. A copy of the letter can be downloaded here. The second quarter results were a complete reversal of Q1 results, with the portfolio appreciating 23.0% (gross) and 23.3% (net), outperforming the index's 17.3%. The overall market surge contributed to this performance, alongside several positive developments related to the firm's holdings. Since inception, the fund has returned ~16% gross and ~12% net per annum, surpassing the benchmark's return of ~9% per annum. The portfolio is highly concentrated, with QDEL as the largest holding, creating volatility. Despite mixed results, the firm remains confident in the portfolio, particularly with QDEL viewed as a key investment opportunity. Potential for further growth is expected from several large investments with promising catalysts. In addition, you can check the Strategy's top 5 holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, McIntyre Partnerships highlighted QuidelOrtho Corporation NASDAQ:QDEL). QuidelOrtho Corporation (NASDAQ:QDEL) is a diagnostic testing solutions company that provides solutions across Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. On August 7, 2026, QuidelOrtho Corporation (NASDAQ:QDEL) closed at $12.28 per share, reflecting a market capitalization of $837.72 million. QuidelOrtho Corporation (NASDAQ:QDEL) posted a one‑month return of ‑837.72%, while its shares lost 46.55% over the past 52 weeks."
McIntyre Partnerships stated the following regarding QuidelOrtho Corporation (NASDAQ:QDEL) in its Q2 2026 investor letter:
"As I argued in the Q1 letter outlining our thesis, QuidelOrtho Corporation (NASDAQ:QDEL) is essentially three different businesses operating under one corporate entity, and a division could be sold to deleverage the company. QDEL appears to be following this path. According to the FT article, QDEL is looking to sell its POC division for roughly $1.5B. POC is the old Quidel business, and the transaction would essentially undo the 2022 merger of Quidel and Ortho. ***** uming a sale near the rumored price, the QDEL RemainCo would be ~2.5x levered and consist of the legacy Ortho business. Critically, the driver of QDEL's repeated missed estimates over the last three years is the legacy Quidel business, while legacy Ortho has been a steady performer, albeit with negative Chinese regulatory news in Q1. Once the Chinese regulations are finalized in the coming months, I believe the legacy Ortho business will return to its historical, consistent high single-digit EBITDA growth.
Additionally, I believe Q2 will mark a low point for cash flow generation, a frequent bear point. As QDEL delevers and exits the volatile flu and COVID business, I believe the stock can reweight towards peers in the 11-15x EV/EBITDA range. If not, I believe the company will
In its Q2 2026 investor letter, McIntyre Partnerships highlighted QuidelOrtho Corporation NASDAQ:QDEL). QuidelOrtho Corporation (NASDAQ:QDEL) is a diagnostic testing solutions company that provides solutions across Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. On August 7, 2026, QuidelOrtho Corporation (NASDAQ:QDEL) closed at $12.28 per share, reflecting a market capitalization of $837.72 million. QuidelOrtho Corporation (NASDAQ:QDEL) posted a one‑month return of ‑837.72%, while its shares lost 46.55% over the past 52 weeks."
McIntyre Partnerships stated the following regarding QuidelOrtho Corporation (NASDAQ:QDEL) in its Q2 2026 investor letter:
"As I argued in the Q1 letter outlining our thesis, QuidelOrtho Corporation (NASDAQ:QDEL) is essentially three different businesses operating under one corporate entity, and a division could be sold to deleverage the company. QDEL appears to be following this path. According to the FT article, QDEL is looking to sell its POC division for roughly $1.5B. POC is the old Quidel business, and the transaction would essentially undo the 2022 merger of Quidel and Ortho. ***** uming a sale near the rumored price, the QDEL RemainCo would be ~2.5x levered and consist of the legacy Ortho business. Critically, the driver of QDEL's repeated missed estimates over the last three years is the legacy Quidel business, while legacy Ortho has been a steady performer, albeit with negative Chinese regulatory news in Q1. Once the Chinese regulations are finalized in the coming months, I believe the legacy Ortho business will return to its historical, consistent high single-digit EBITDA growth.
Additionally, I believe Q2 will mark a low point for cash flow generation, a frequent bear point. As QDEL delevers and exits the volatile flu and COVID business, I believe the stock can reweight towards peers in the 11-15x EV/EBITDA range. If not, I believe the company will
19 days ago
Micron (NASDAQ: MU) stock got hit with a big pullback in July's trading. The memory-chip leader's share price fell 28.7% in a month that saw the S&P 500 trade roughly flat and the Nasdaq Composite's level fall by 2.6%, according to data from S&P Global Market Intelligence.
On the heels of massive gains across the first half of 2026, Micron stock suffered a huge sell-off in July in response to earnings reports and guidance from South Korean memory chip leaders and potential threats posed by the rise of competition from Chinese companies. In addition to those bearish catalysts, Micron's share price was also pressured by macroeconomic and geopolitical dynamics.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Micron stock moved lower in July due to broad concerns that artificial intelligence (AI) hardware stocks were overvalued, the market's negative reaction to Samsung's capital expenditures guidance, and fears that competition from Chinese companies could hurt pricing power. Then, South Korea's SK Hynix posted its second-quarter results on July 28 -- and the market was not happy with the results. While the company delivered robust sales and earnings growth in the period, the performance actually fell substantially short of ******* ysts' expectations. SK Hynix is another major player in the memory chip industry, and some investors interpreted the company's sales and earnings miss in Q2 as an indication that expectations for Micron may have been overly lofty as well.
Along with those pressures, Micron stock also lost ground last month due to concerns about the Iran war and inflationary trends. Strikes between the U.S. and Iran reescalated last month, creating another source of volatility for the broader market. While energy prices declined in June thanks to a drawdown in the conflict, they began climbing rapidly again last month. With oil prices rising due to disruptions in shipping through the Strait of Hormuz, investors became fearful of a reacceleration of inflation and potential moves to raise interest rates from the Federal Reserve.
#Stock
On the heels of massive gains across the first half of 2026, Micron stock suffered a huge sell-off in July in response to earnings reports and guidance from South Korean memory chip leaders and potential threats posed by the rise of competition from Chinese companies. In addition to those bearish catalysts, Micron's share price was also pressured by macroeconomic and geopolitical dynamics.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Micron stock moved lower in July due to broad concerns that artificial intelligence (AI) hardware stocks were overvalued, the market's negative reaction to Samsung's capital expenditures guidance, and fears that competition from Chinese companies could hurt pricing power. Then, South Korea's SK Hynix posted its second-quarter results on July 28 -- and the market was not happy with the results. While the company delivered robust sales and earnings growth in the period, the performance actually fell substantially short of ******* ysts' expectations. SK Hynix is another major player in the memory chip industry, and some investors interpreted the company's sales and earnings miss in Q2 as an indication that expectations for Micron may have been overly lofty as well.
Along with those pressures, Micron stock also lost ground last month due to concerns about the Iran war and inflationary trends. Strikes between the U.S. and Iran reescalated last month, creating another source of volatility for the broader market. While energy prices declined in June thanks to a drawdown in the conflict, they began climbing rapidly again last month. With oil prices rising due to disruptions in shipping through the Strait of Hormuz, investors became fearful of a reacceleration of inflation and potential moves to raise interest rates from the Federal Reserve.
#Stock
20 days ago
Oracle's (NYSE: ORCL) stock has rallied 27% over the past two weeks. Let's see what catalysts drove its stock higher, and if it can maintain its momentum over the next few months.
The biggest catalyst for Oracle's stock was the expansion of its partnership with Alphabet's (NASDAQ: GOOG) (NASDAQ: GOOGL) Google on July 30. Google will integrate its advanced Gemini AI models into Oracle's AI Agent Studio, enabling Oracle's Cloud Infrastructure (OCI) customers to build and deploy AI agents with Google's AI software.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
OCI has been Oracle's primary growth engine over the past year. In fiscal 2026 (which ended on May 31), its cloud infrastructure revenue surged 77% to $18.1 billion, accounting for 27% of its top line, as more companies used its high-peformance GPU clusters to power AI applications.
OCI is much smaller than Amazon (NASDAQ: AMZN) Web Services (AWS), Microsoft (NASDAQ: MSFT) Azure, and Google Cloud, but it integrates its services into those larger cloud infrastructure platforms so that its enterprise customers can run their workloads seamlessly across multiple cloud providers without being locked into a single ecosystem. Its expanded partnership with Google complements that strategy and increases its exposure to the AI market.
#cloud #Google #infrastructure #Stock
The biggest catalyst for Oracle's stock was the expansion of its partnership with Alphabet's (NASDAQ: GOOG) (NASDAQ: GOOGL) Google on July 30. Google will integrate its advanced Gemini AI models into Oracle's AI Agent Studio, enabling Oracle's Cloud Infrastructure (OCI) customers to build and deploy AI agents with Google's AI software.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
OCI has been Oracle's primary growth engine over the past year. In fiscal 2026 (which ended on May 31), its cloud infrastructure revenue surged 77% to $18.1 billion, accounting for 27% of its top line, as more companies used its high-peformance GPU clusters to power AI applications.
OCI is much smaller than Amazon (NASDAQ: AMZN) Web Services (AWS), Microsoft (NASDAQ: MSFT) Azure, and Google Cloud, but it integrates its services into those larger cloud infrastructure platforms so that its enterprise customers can run their workloads seamlessly across multiple cloud providers without being locked into a single ecosystem. Its expanded partnership with Google complements that strategy and increases its exposure to the AI market.
#cloud #Google #infrastructure #Stock
23 days ago
Meta Platforms (META) continues to grow rapidly, and evidence suggests that artificial intelligence (AI) is making its ads more effective. Still, the company's financial results appear unlikely to get a huge boost from AI in the bigger picture, while Meta also does not appear to have many imminent positive catalysts on the way. Meta's core ad business is also quite vulnerable to a potential drop in consumer spending, which could eventually be triggered by elevated oil prices and tariffs.
Conversely, Amazon (AMZN) is benefiting tremendously from the AI boom and appears likely to continue to do so. Amazon has multiple, needle-moving businesses working for it as well, making the case for AMZN stock even stronger.
Jeff Bezos Says He's Selling $1 Billion In Amazon Stock Every Year to Fund Blue Origin — 'It's The Most Important Work I'm Doing'
Apple's New CEO Is Bringing a Familiar Face Back From Retirement. The Shift Is Happening.
Nasdaq Futures Climb as Tech Rally Continues on Palantir Boost, U.S. JOLTS Report and ****** eX Earnings on Tap
#amzn #continues #boost #still
Conversely, Amazon (AMZN) is benefiting tremendously from the AI boom and appears likely to continue to do so. Amazon has multiple, needle-moving businesses working for it as well, making the case for AMZN stock even stronger.
Jeff Bezos Says He's Selling $1 Billion In Amazon Stock Every Year to Fund Blue Origin — 'It's The Most Important Work I'm Doing'
Apple's New CEO Is Bringing a Familiar Face Back From Retirement. The Shift Is Happening.
Nasdaq Futures Climb as Tech Rally Continues on Palantir Boost, U.S. JOLTS Report and ****** eX Earnings on Tap
#amzn #continues #boost #still
23 days ago
NUGT surged 14% and AGQ jumped 9% today, but both funds remain deeply negative for 2026 despite the rally.
Kinross posted record free cash flow of $840 million in Q2; Gold Fields grew production 15% at a $4,855/oz realized gold price.
NUGT's 10-year return of -79% shows how daily-reset compounding decay can devastate leveraged ETF holders over any multi-day window.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
Leveraged precious-metals ETFs are the standouts on Wall Street this session, with the Direxion Daily Gold Miners Bull 2X Shares (NYSEARCA:NUGT) surging 14.46% and the ProShares Ultra Silver (NYSEARCA:AGQ) climbing 9.39% as both gold and silver spot prices rally, both up between 4% and 5%. The SPDR Gold Shares (NYSEARCA:GLD) is up 4.3% on the session, and traders are attributing the metals bid to a softer US dollar, easing Treasury yields, and market expectations around cooling inflation and geopolitical de-escalation. Those are the catalysts being cited on desks rather than any single confirmed event.
#shares
Kinross posted record free cash flow of $840 million in Q2; Gold Fields grew production 15% at a $4,855/oz realized gold price.
NUGT's 10-year return of -79% shows how daily-reset compounding decay can devastate leveraged ETF holders over any multi-day window.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.
Leveraged precious-metals ETFs are the standouts on Wall Street this session, with the Direxion Daily Gold Miners Bull 2X Shares (NYSEARCA:NUGT) surging 14.46% and the ProShares Ultra Silver (NYSEARCA:AGQ) climbing 9.39% as both gold and silver spot prices rally, both up between 4% and 5%. The SPDR Gold Shares (NYSEARCA:GLD) is up 4.3% on the session, and traders are attributing the metals bid to a softer US dollar, easing Treasury yields, and market expectations around cooling inflation and geopolitical de-escalation. Those are the catalysts being cited on desks rather than any single confirmed event.
#shares
24 days ago
There are six reasons the U.S. stock market could reach new highs in August, according to Fundstrat.
Equities have broadly flatlined over the past two months, with the S&P 500 SPX down 1% and the Nasdaq COMP down by about 2% since the beginning of June. But "as long as we have a healthy economy, consolidations are healthy," said Tom Lee, head of research at the market-strategy firm, adding that he believes stocks are poised to respond to positive catalysts.
If I marry my girlfriend, 67, will she lose her Supplemental Security Income and divorced spouse benefits?
The S&P 500 just hit a new high. 'Big Short' investor Michael Burry thinks it could bring a 1987-style fall.
Retail investors are buying the dip on ***** eX's stock before more shares flood the market
#Stock #healthy #august #equities
Equities have broadly flatlined over the past two months, with the S&P 500 SPX down 1% and the Nasdaq COMP down by about 2% since the beginning of June. But "as long as we have a healthy economy, consolidations are healthy," said Tom Lee, head of research at the market-strategy firm, adding that he believes stocks are poised to respond to positive catalysts.
If I marry my girlfriend, 67, will she lose her Supplemental Security Income and divorced spouse benefits?
The S&P 500 just hit a new high. 'Big Short' investor Michael Burry thinks it could bring a 1987-style fall.
Retail investors are buying the dip on ***** eX's stock before more shares flood the market
#Stock #healthy #august #equities
24 days ago
The San Diego Padres scored early and often in a convincing 9-4 win over the Arizona Diamondbacks to even the four-game series at a game apiece. It was their ninth win in the last 11 games, moving the Padres one game back of the Diamondbacks in the National League Wild-Card standings.
This sets up a crucial third game in the four-game set. The victor could gain much-needed momentum in securing the final playoff spot.
One of the catalysts in the Padres' ability to roar back into the Wild-Card chase has been their offense. Last night, the lineup erupted for 16 hits and nine runs in the road victory. Manny Machado was the hitting star with three hits and four RBIs. Jackson Merrill continued his hot streak with a three-hit night and two RBIs. Jake Cronenworth also contributed with three hits and an RBI.
View Link
Since the All-Star break, the team's hitting numbers have been outstanding. The Friars have a team batting average of .291 with 139 hits and 20 home runs. The hope is the suddenly hot offense combined with improved starting pitching will help the club to gain more ground in the heated NL Wild-Card race.
#wild #four #diamondbacks #last
This sets up a crucial third game in the four-game set. The victor could gain much-needed momentum in securing the final playoff spot.
One of the catalysts in the Padres' ability to roar back into the Wild-Card chase has been their offense. Last night, the lineup erupted for 16 hits and nine runs in the road victory. Manny Machado was the hitting star with three hits and four RBIs. Jackson Merrill continued his hot streak with a three-hit night and two RBIs. Jake Cronenworth also contributed with three hits and an RBI.
View Link
Since the All-Star break, the team's hitting numbers have been outstanding. The Friars have a team batting average of .291 with 139 hits and 20 home runs. The hope is the suddenly hot offense combined with improved starting pitching will help the club to gain more ground in the heated NL Wild-Card race.
#wild #four #diamondbacks #last
